Your browser is no longer supported. Please, upgrade your browser.
Settings
TARS [NASD]
Tarsus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own17.00% Shs Outstand20.67M Perf Week-7.26%
Market Cap841.68M Forward P/E- EPS next Y-2.62 Insider Trans0.00% Shs Float13.52M Perf Month-7.79%
Income- PEG- EPS next Q-0.66 Inst Own48.90% Short Float2.95% Perf Quarter66.20%
Sales- P/S- EPS this Y-254.10% Inst Trans- Short Ratio3.80 Perf Half Y-
Book/sh- P/B- EPS next Y-14.90% ROA- Target Price41.50 Perf Year-
Cash/sh4.18 P/C9.75 EPS next 5Y- ROE- 52W Range15.32 - 63.69 Perf YTD-1.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.07% Beta-
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low165.71% ATR5.41
Employees12 Current Ratio14.50 Sales Q/Q- Oper. Margin- RSI (14)50.46 Volatility9.27% 11.21%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.36 Prev Close42.02
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume105.01K Price40.72
Recom1.20 SMA20-5.64% SMA5018.85% SMA20029.67% Volume37,282 Change-3.09%
Nov-10-20Initiated Raymond James Strong Buy $39
Nov-10-20Initiated Ladenburg Thalmann Buy $42
Nov-10-20Initiated Jefferies Buy $35
Nov-10-20Initiated BofA Securities Buy $33
Jan-19-21 08:30AM  
Jan-18-21 08:43AM  
Jan-07-21 09:24AM  
Jan-05-21 05:00PM  
Dec-23-20 07:00AM  
Dec-21-20 07:00AM  
Nov-19-20 03:24PM  
Nov-13-20 07:35PM  
Oct-20-20 04:05PM  
Oct-16-20 06:05PM  
Oct-15-20 08:35PM  
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
PASG Passage Bio, Inc. daily Stock Chart
PASG [NASD]
Passage Bio, Inc.
Index- P/E- EPS (ttm)- Insider Own19.38% Shs Outstand45.50M Perf Week-33.59%
Market Cap952.86M Forward P/E- EPS next Y-3.12 Insider Trans-0.01% Shs Float36.71M Perf Month-18.17%
Income- PEG- EPS next Q-0.72 Inst Own79.30% Short Float5.16% Perf Quarter12.11%
Sales- P/S- EPS this Y-257.30% Inst Trans0.40% Short Ratio8.08 Perf Half Y3.61%
Book/sh7.45 P/B2.66 EPS next Y-10.60% ROA- Target Price29.13 Perf Year-
Cash/sh6.98 P/C2.84 EPS next 5Y- ROE- 52W Range8.09 - 38.23 Perf YTD-22.53%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.18% Beta-
Dividend %- Quick Ratio18.30 Sales past 5Y- Gross Margin- 52W Low144.87% ATR2.42
Employees20 Current Ratio18.30 Sales Q/Q- Oper. Margin- RSI (14)33.55 Volatility10.86% 8.20%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume17.63 Prev Close22.82
ShortableYes LT Debt/Eq0.00 EarningsNov 10 BMO Payout- Avg Volume234.58K Price19.81
Recom2.40 SMA20-27.00% SMA50-17.03% SMA200-3.26% Volume4,135,453 Change-13.19%
Jan-04-21Upgrade JP Morgan Neutral → Overweight $25 → $35
Dec-11-20Initiated Citigroup Neutral $28
Aug-14-20Downgrade JP Morgan Overweight → Neutral $25
Jun-25-20Downgrade Goldman Buy → Neutral $28
Mar-25-20Initiated Chardan Capital Markets Buy $30
Mar-24-20Initiated JP Morgan Overweight $25
Mar-24-20Initiated Goldman Buy $27
Mar-24-20Initiated Cowen Outperform
Jan-22-21 02:22PM  
Jan-21-21 07:48PM  
Jan-19-21 04:06PM  
07:00AM  
Jan-13-21 10:25AM  
Jan-11-21 07:00AM  
Jan-04-21 04:01PM  
07:00AM  
Dec-16-20 08:00AM  
Dec-15-20 11:10PM  
Dec-11-20 08:11AM  
Dec-10-20 04:01PM  
Dec-07-20 07:00AM  
Nov-24-20 03:55AM  
Nov-23-20 04:01PM  
Nov-11-20 04:30PM  
07:00AM  
Nov-10-20 07:00AM  
Nov-09-20 07:00AM  
Nov-04-20 07:00AM  
Oct-28-20 07:00AM  
Oct-26-20 07:00AM  
Oct-14-20 08:30AM  
Oct-13-20 04:30PM  
Oct-06-20 07:00AM  
Sep-25-20 07:00AM  
Sep-17-20 07:00AM  
Sep-03-20 08:00AM  
Aug-26-20 02:58PM  
Aug-13-20 07:00AM  
Aug-07-20 04:01PM  
Jun-26-20 08:00AM  
Jun-04-20 11:17AM  
08:00AM  
May-28-20 08:35AM  
May-21-20 08:00AM  
May-12-20 05:00PM  
May-11-20 07:00AM  
May-07-20 07:30AM  
May-04-20 08:00AM  
Apr-21-20 08:00AM  
Apr-08-20 08:00AM  
Mar-27-20 08:00AM  
Mar-09-20 04:30PM  
Mar-05-20 08:00AM  
Feb-27-20 07:25PM  
Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quigley Jill M.Chief Operating OfficerJan 20Sale30.011,30039,011295,284Jan 22 05:54 PM
PHAT Phathom Pharmaceuticals, Inc. daily Stock Chart
PHAT [NASD]
Phathom Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.81 Insider Own17.16% Shs Outstand25.92M Perf Week3.69%
Market Cap1.26B Forward P/E- EPS next Y-4.10 Insider Trans-3.42% Shs Float9.60M Perf Month7.45%
Income-173.40M PEG- EPS next Q-1.03 Inst Own70.40% Short Float8.43% Perf Quarter4.75%
Sales- P/S- EPS this Y84.30% Inst Trans-0.12% Short Ratio6.23 Perf Half Y27.48%
Book/sh6.03 P/B6.58 EPS next Y-16.10% ROA-69.00% Target Price51.33 Perf Year5.82%
Cash/sh7.12 P/C5.57 EPS next 5Y- ROE-88.70% 52W Range22.06 - 64.54 Perf YTD19.39%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.55% Beta-
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low79.78% ATR2.20
Employees25 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)55.50 Volatility3.96% 5.27%
OptionableYes Debt/Eq0.30 EPS Q/Q52.60% Profit Margin- Rel Volume1.00 Prev Close39.02
ShortableYes LT Debt/Eq0.26 Earnings- Payout- Avg Volume129.85K Price39.66
Recom2.30 SMA2010.27% SMA50-1.98% SMA2004.52% Volume129,996 Change1.64%
Jun-26-20Downgrade Goldman Neutral → Sell $34
Nov-20-19Initiated Evercore ISI Outperform
Nov-19-19Initiated Needham Buy $40
Nov-19-19Initiated Jefferies Buy $32
Nov-19-19Initiated Goldman Neutral $32
Jan-19-21 08:30AM  
Dec-16-20 06:43PM  
Dec-15-20 04:01PM  
Dec-14-20 08:30AM  
Dec-08-20 09:00AM  
Dec-02-20 11:33PM  
Nov-30-20 04:05PM  
Nov-27-20 08:00AM  
Nov-19-20 04:05PM  
Nov-13-20 04:05PM  
Nov-10-20 04:05PM  
Nov-04-20 04:05PM  
Sep-09-20 08:30AM  
Aug-06-20 08:30AM  
Jul-13-20 08:30AM  
Jun-15-20 08:30AM  
Jun-12-20 10:25PM  
May-28-20 04:30PM  
May-12-20 08:30AM  
Apr-09-20 04:30PM  
Mar-19-20 08:30AM  
Feb-25-20 04:35PM  
Jan-16-20 09:00AM  
Jan-06-20 08:30AM  
Dec-23-19 08:30AM  
Dec-02-19 08:30AM  
08:30AM  
Nov-26-19 08:30AM  
08:30AM  
Nov-25-19 08:30AM  
08:30AM  
Nov-13-19 04:05PM  
Oct-29-19 04:05PM  
Oct-25-19 05:10PM  
Oct-24-19 08:25PM  
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Socks David ADirectorJan 12Sale36.0727,165979,7951,532,945Jan 13 05:07 PM
Socks David ADirectorJan 11Sale34.9212,835448,2431,560,110Jan 13 05:07 PM
Socks David ADirectorDec 17Sale40.7448,2121,964,3761,572,945Dec 18 08:01 PM
Socks David ADirectorDec 16Sale47.5331,4461,494,5191,621,157Dec 18 08:01 PM
Nabulsi AzmiChief Operating OfficerDec 02Sale45.267,302330,513838,200Dec 03 06:01 PM
Nabulsi AzmiChief Operating OfficerDec 01Sale44.207,198318,176845,502Dec 03 06:01 PM
Socks David ADirectorNov 11Sale38.976,877268,0211,652,603Nov 12 04:13 PM
Socks David ADirectorNov 10Sale41.6912,681528,6721,659,480Nov 12 04:13 PM
Socks David ADirectorNov 09Sale42.3310,784456,5061,676,562Nov 12 04:13 PM
Nabulsi AzmiChief Operating OfficerNov 02Sale36.8314,500534,026852,700Nov 03 06:40 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerApr 01Buy24.86117,6002,923,6423,825,008Apr 03 04:30 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMar 31Buy24.5530,600751,2643,707,408Mar 31 05:02 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMar 27Buy24.6030,000738,0003,676,808Mar 31 05:02 PM
MIRM Mirum Pharmaceuticals, Inc. daily Stock Chart
MIRM [NASD]
Mirum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.43 Insider Own0.40% Shs Outstand25.13M Perf Week4.44%
Market Cap567.60M Forward P/E- EPS next Y-4.25 Insider Trans6.77% Shs Float9.54M Perf Month4.39%
Income-84.00M PEG- EPS next Q-0.97 Inst Own71.10% Short Float10.67% Perf Quarter8.56%
Sales- P/S- EPS this Y-202.90% Inst Trans0.22% Short Ratio5.50 Perf Half Y-8.93%
Book/sh4.78 P/B4.03 EPS next Y-17.70% ROA-54.50% Target Price- Perf Year0.10%
Cash/sh4.54 P/C4.24 EPS next 5Y- ROE-61.90% 52W Range9.14 - 27.43 Perf YTD10.42%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.71% Beta-
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin- 52W Low110.94% ATR1.32
Employees67 Current Ratio7.40 Sales Q/Q- Oper. Margin- RSI (14)50.07 Volatility5.38% 6.01%
OptionableNo Debt/Eq0.00 EPS Q/Q-30.50% Profit Margin- Rel Volume0.50 Prev Close18.84
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume185.10K Price19.28
Recom1.40 SMA202.82% SMA50-4.13% SMA200-0.63% Volume92,701 Change2.34%
Aug-07-20Upgrade Raymond James Outperform → Strong Buy $28 → $48
Aug-03-20Initiated H.C. Wainwright Buy $52
Jul-31-20Initiated Piper Sandler Overweight $77
Jun-25-20Initiated Robert W. Baird Outperform $30
Aug-12-19Initiated ROTH Capital Buy $33
Aug-12-19Initiated Raymond James Outperform $28
Aug-12-19Initiated Guggenheim Buy $18
Aug-12-19Initiated Evercore ISI Outperform
Aug-12-19Initiated Citigroup Buy $21
Jan-14-21 09:00AM  
Jan-12-21 09:00AM  
Jan-08-21 06:17PM  
Jan-04-21 08:30AM  
Dec-30-20 02:45AM  
Dec-22-20 08:55AM  
Dec-14-20 09:00PM  
07:00AM  
Dec-10-20 10:33PM  
07:41PM  
Dec-09-20 09:00AM  
Dec-07-20 09:00AM  
Nov-30-20 08:30AM  
Nov-23-20 09:30AM  
Nov-15-20 06:00PM  
Nov-13-20 08:10AM  
Nov-12-20 09:00AM  
Nov-10-20 07:00PM  
Nov-05-20 08:30AM  
Nov-02-20 08:30AM  
Oct-26-20 08:30AM  
Oct-15-20 08:55AM  
08:45AM  
Oct-14-20 10:29AM  
Oct-13-20 04:05PM  
Sep-11-20 04:30PM  
07:00AM  
Sep-01-20 09:00AM  
Aug-29-20 08:45AM  
Aug-11-20 05:30PM  
09:42AM  
09:37AM  
Aug-07-20 04:05PM  
Aug-06-20 04:05PM  
Jul-10-20 05:00PM  
Jun-22-20 02:06PM  
Jun-11-20 04:10PM  
Jun-02-20 08:30AM  
May-29-20 10:05AM  
May-11-20 05:01PM  
May-07-20 04:05PM  
Apr-28-20 04:19PM  
Mar-12-20 04:02PM  
Feb-18-20 04:01PM  
Jan-16-20 09:00AM  
Jan-14-20 09:00AM  
Jan-08-20 08:15PM  
Dec-24-19 10:40AM  
Dec-17-19 07:56AM  
Dec-16-19 08:00AM  
Dec-13-19 04:28PM  
Nov-25-19 08:30AM  
08:30AM  
Nov-08-19 08:05AM  
Nov-06-19 04:05PM  
Oct-28-19 04:05PM  
08:30AM  
Oct-21-19 10:15AM  
Oct-01-19 04:30PM  
Sep-26-19 08:35AM  
08:30AM  
Aug-28-19 04:01PM  
Aug-12-19 09:57AM  
Jul-17-19 06:33PM  
Jul-15-19 10:10AM  
Jul-12-19 12:10PM  
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tucker Edwin JonathanChief Medical OfficerDec 28Option Exercise7.704,16732,08636,442Dec 29 04:24 PM
Clements IanChief Financial OfficerDec 23Buy18.612,47045,9757,841Dec 28 04:12 PM
Peetz ChristopherPresident and CEODec 23Buy18.705,00093,480201,570Dec 28 04:06 PM
Tucker Edwin JonathanChief Medical OfficerOct 30Option Exercise7.7025,000192,50031,000Nov 03 05:09 PM
Tucker Edwin JonathanChief Medical OfficerMar 20Buy11.902,50029,7406,000Mar 23 04:47 PM
Tucker Edwin JonathanChief Medical OfficerMar 19Buy9.912,00019,8183,500Mar 23 04:47 PM